[LAPAROSCOPIC MYOMECTOMY AFTER ULIPRISTAL ACFTATF TRFATMFMT.]

Area of Science:

• Gynecology
• Reproductive Medicine
• Oncology

Background:

• Uterine myomas (fibroids) are the most frequent benign uterine tumors in women of reproductive age, affecting 20-25% globally.
• Symptoms like heavy menstrual bleeding, pelvic pain, and reproductive dysfunction significantly impact women's health and quality of life.
• Current medical treatments cannot completely eliminate fibroids, necessitating effective management strategies.

Purpose of the Study:

• To review the efficacy and safety of ulipristal acetate (UPA) as a preoperative treatment for uterine fibroids.
• To compare UPA with existing treatments, such as gonadotropin-releasing hormone agonists.
• To assess the role of UPA in improving patient outcomes and reducing the need for adjuvant surgery.

Main Methods:

• Systematic review of clinical trials and observational studies on UPA for uterine fibroid treatment.
• Analysis of data on fibroid volume reduction, symptom control, and surgical outcomes.
• Comparison of efficacy and safety profiles between UPA and other medical therapies.

Main Results:

• Ulipristal acetate (UPA) has demonstrated significant efficacy in reducing uterine fibroid volume and controlling heavy menstrual bleeding.
• UPA offers an alternative to gonadotropin-releasing hormone agonists for preoperative fibroid management.
• Approximately one-third of patients treated with UPA may still require adjuvant surgical intervention.

Conclusions:

• Ulipristal acetate (UPA) is an approved and effective medical treatment for uterine fibroids in Europe since 2012.
• UPA provides a valuable option for preoperative management, improving symptoms and potentially reducing surgical extent.
• Further research may explore long-term outcomes and optimal patient selection for UPA therapy.